- Home
- HQ vs SANA Comparison
HQ vs SANA Comparison
Compare HQ & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HQ | SANA |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 674.1M | 688.5M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HQ | SANA |
|---|---|---|
| Price | $14.10 | $2.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $20.50 | $8.43 |
| AVG Volume (30 Days) | 89.9K | ★ 3.0M |
| Earning Date | 11-10-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.24 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.29 | $2.22 |
| 52 Week High | $45.00 | $5.49 |
Technical Indicators
Market Signals| Indicator | HQ | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 45.79 | 45.20 |
| Support Level | $13.68 | $2.22 |
| Resistance Level | $14.43 | $3.41 |
| Average True Range (ATR) | 1.11 | 0.16 |
| MACD | 0.06 | 0.06 |
| Stochastic Oscillator | 47.94 | 61.15 |
Price Performance
Historical ComparisonAbout HQ Horizon Quantum Holdings Ltd. Class A Ordinary Shares
Horizon Quantum Holdings Ltd is building software infrastructure to make quantum computers accessible to commercial enterprises and hardware providers. By bridging the gap between hardware and applications, the company seeks to equip developers, researchers, and enterprises with the quantum software infrastructure needed to solve real-world problems. The company is developing tools that can automatically accelerate code written for conventional computers on quantum computers.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.